Saudi Arabia RUO Immunoassay Market - Strategic Insights and Forecasts (2026-2031)

The Saudi Arabia RUO Immunoassay market is forecast to grow at a Compound Annual Growth Rate (CAGR) of 5.9%. This expansion is projected to increase the market value from USD 0.9 billion in 2026 to USD 1.2 billion by 2031.

The market is segmented by product type into Immunoassay Kits, Immunoassay Reagents, Microplates, Analysers, Microplate Washers, and other products. Immunoassay Kits are particularly important as they provide standardized, ready-to-use solutions for detecting various hormones, proteins, or pathogens, enhancing reliability and reducing human error in diagnostic and research settings.

The market utilizes various sample types, including Plasma, Blood Serum, Urine, Saliva, Cell or Tissue Culture Medium, and others. Plasma is especially significant due to its essential clotting factors, antibodies, and proteins, making it crucial for the immunoassay-based detection of infectious diseases, autoimmune conditions, and neoplasms, as well as for monitoring therapeutic responses.

Saudi Arabia's Vision 2030 is a significant driver, with the government investing over US$65 billion in healthcare infrastructure, including new hospitals and primary care sites. This initiative promotes the establishment of new facilities, digitisation of health, and early disease detection, directly boosting the adoption and application of immunoassays in both clinical and research environments.

Major applications for RUO immunoassays in Saudi Arabia include detecting oncology biomarkers, supporting infectious disease diagnostics, expanding plasma analysis, and enhancing cardiology testing. The market is also propelled by increased academic research, biotech R&D, and the rising prevalence of chronic and infectious diseases within the country.

Saudi Arabia has the biggest In Vitro Diagnostics (IVD) market in the GCC due to the increasing prevalence of chronic and infectious diseases and an ageing population. Furthermore, substantial government investment under Vision 2030 into healthcare infrastructure, digitisation, and early detection initiatives, including hundreds of new hospitals and primary care sites, solidifies its market leadership.